Drug Development and Clinical Trials

Bringing a new DRUG to market requires years of careful testing. Why? Because untested drugs can KILL people (history is full of disasters — like THALIDOMIDE in the 1960s causing thousands of birth defects). Modern processes are designed to balance speed (urgent need) with safety. Most candidate drugs FAIL during testing. Only ~1 in 10 entering human trials makes it to market. The high failure rate is part of why drugs are expensive.

The phases. PRECLINICAL: lab and animal testing. Most drugs fail here. PHASE I: first in humans (~20-100 healthy volunteers); checks safety and dosing. PHASE II: a few hundred patients with the disease; checks effectiveness and more safety. PHASE III: thousands of patients; large randomized controlled trials comparing the drug to placebo or standard treatment. PHASE IV: post-approval surveillance for rare side effects. Each phase has go/no-go decisions. Total: 10-15 years from discovery to pharmacy shelf, $1-2.5 BILLION per approved drug.

Modern progress. mRNA vaccines for COVID-19 went from sequencing to approved in <1 YEAR — unprecedented speed enabled by decades of mRNA research, parallel testing instead of sequential, and unlimited resources. Modern computer modeling and AI are accelerating drug discovery. ADAPTIVE clinical trials adjust based on early data. PRECISION MEDICINE enables smaller trials targeting specific patient subgroups. The pace is increasing — though caution remains essential.

Drug development is one of human science's most ambitious enterprises. It is slow, expensive, and full of failure — but each success saves countless lives. The system, while imperfect, works.